Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:VNDA News 31 December 2025 - 1 January 2026

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

NEW YORK, January 1, 2026, 13:41 ET — Market closed Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq The moves matter because regulatory calls can dominate small-cap biotech even when the broader healthcare sector…
1 January 2026
······
Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

NEW YORK, December 31, 2025, 13:38 ET — Regular session Vanda Pharmaceuticals shares jumped 28.1% to $9.01 at 1:38 p.m. ET on Wednesday after the company said the U.S. Food and Drug Administration approved Nereus (tradipitant) to prevent vomiting induced by motion. Vanda said the oral drug is a neurokinin-1 (NK-1) receptor antagonist — meaning it blocks a receptor involved…
31 December 2025
····
S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

NEW YORK, December 31, 2025, 1:26 PM ET — Regular session U.S. stocks edged lower on Wednesday in thin year-end trading. The Dow Jones Industrial Average fell 114.33 points, or 0.24%, to 48,252.73; the S&P 500 lost 16.62 points, or 0.24%, to 6,879.62; and the Nasdaq Composite slipped 51.05 points, or 0.22%, to 23,368.03. Reuters The drift lower on the…
31 December 2025
·····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

NEW YORK, December 31, 2025, 04:27 ET — Premarket Vanda Pharmaceuticals’ shares surged about 18% in premarket trading on Wednesday after the U.S. Food and Drug Administration approved its motion-sickness vomiting drug, Nereus (tradipitant). StockAnalysis The approval matters now because Vanda is moving from a long-running regulatory story to a commercial one, with investors shifting quickly to questions of launch…
31 December 2025
····

Stock Market Today

  • Euronext Dublin GEM Notice Highlights Market Data Providers
    January 29, 2026, 4:07 AM EST. Euronext Dublin released a GEM notice outlining key market data providers including ICE Data Services and FactSet, both integral in supplying reference and market data. FactSet also provides the CUSIP Database used for securities identification, while SEC filings and related documents come via Quartr. TradingView supports broader market analytics. These contributors underpin transparency and data accuracy for market participants on Euronext Dublin's Growth Enterprise Market (GEM).
Go toTop